EPIZYME
Live / Registered — Registered (as of 09 Feb 2021)
What this means for you
Registered since 09 Feb 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88979999
- Registration number
- 6268511
- Mark type
- Stylized text
- Filed
- 30 May 2019
- Published for opposition
- 21 Apr 2020
- Registered
- 09 Feb 2021
- Attorney of record
- Douglas R. Wolf
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical products for the treatment of human diseases and disorders, namely, cancer, cell proliferative diseases and disorders, hematological diseases and disorders, and diseases and disorders driven by epigenetic mechanisms
- Class 042 — Scientific and technological services: pharmaceutical research and development in the fields of cancer, cell proliferative diseases and disorders, hematological diseases and disorders, genetic diseases and disorders, and diseases and disorders driven by epigenetic mechanisms; all of the foregoing for human medicinal purposes
Owner
- Epizyme, Inc., Cambridge, MA, US
- Epizyme, Inc., Cambridge, MA, US
- Epizyme, Inc., Cambridge, MA, US
Prosecution history
- 09 Feb 2026 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 09 Feb 2021 — REGISTERED-PRINCIPAL REGISTER
- 06 Jan 2021 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 05 Jan 2021 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 04 Jan 2021 — STATEMENT OF USE PROCESSING COMPLETE
- 10 Dec 2020 — USE AMENDMENT FILED
- 04 Jan 2021 — DIVISIONAL PROCESSING COMPLETE
- 10 Dec 2020 — DIVISIONAL REQUEST RECEIVED
- 29 Dec 2020 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 10 Dec 2020 — TEAS REQUEST TO DIVIDE RECEIVED
- 10 Dec 2020 — TEAS STATEMENT OF USE RECEIVED
- 16 Jun 2020 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 21 Apr 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 21 Apr 2020 — PUBLISHED FOR OPPOSITION
- 01 Apr 2020 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED